Population Pharmacokinetics and Safety of Intravenous Ceftolozane/Tazobactam in Adult Cystic Fibrosis Patients
A Prospective, Multicenter, Open-Label Study to Assess Population Pharmacokinetics and Safety of Intravenous Ceftolozane/Tazobactam in Adult Cystic Fibrosis Patients Admitted With Acute Pulmonary Exacerbation
Sponsor: Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
This PHASE4 trial investigates Cystic Fibrosis and Cystic Fibrosis Pulmonary Exacerbation and is currently completed. Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) leads this study, which shows 10 recorded versions since 2015 — indicating substantial longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Jan 2024 — Jul 2024 [monthly]
Completed PHASE4
-
Jan 2021 — Jan 2024 [monthly]
Completed PHASE4
-
Sep 2020 — Jan 2021 [monthly]
Completed PHASE4
▶ Show 5 earlier versions
-
Jun 2018 — Sep 2020 [monthly]
Completed PHASE4
-
Jul 2017 — Jun 2018 [monthly]
Completed PHASE4
-
May 2017 — Jul 2017 [monthly]
Completed PHASE4
-
Feb 2017 — May 2017 [monthly]
Completed PHASE4
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE4
First recorded
Sep 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Indiana University Health
- Joseph L. Kuti, PharmD
- St. Christopher's Hospital for Children
- University of North Carolina
For direct contact, visit the study record on ClinicalTrials.gov .